Relapsing CD8+ encephalitis—looking for a solution
Authors:
- 22 June 2016
- journal article
- case report
- Published by BMJ in BMJ Case Reports
- Vol. 2016
Abstract
CD8+ encephalitis (CD8+E) is an emerging and incompletely understood HIV-associated neurological syndrome, typically presenting as a steroid-responsive subacute encephalopathy with prominent white matter changes in patients with apparently well-controlled HIV infection. Some cases can be associated with the phenomenon of ‘viral escape’ (disproportionate replication within the cerebrospinal fluid), but the most important pathophysiology of CD8+E is thought to involve an attack on HIV-infected CD4+ lymphocytes by autoreactive CD8+ cells. We report a case of CD8+E where the initial positive response to steroid treatment was followed by several relapses on withdrawal. This led to the use of mycophenolate mofetil (MMF) as a long-term steroid-sparing agent, which is the first time this approach has been reported in the literature. The patient has now been on treatment with MMF for 10 months and it has been possible to taper the steroids down to a minimal maintenance dose without further relapse.Keywords
This publication has 13 references indexed in Scilit:
- CD8 transverse myelitis in a patient with HIV-1 infectionBMJ Case Reports, 2014
- Varicella zoster virus vasculopathy: clinical features and pathogenesisJournal of NeuroVirology, 2013
- Cellular Composition of Cerebrospinal Fluid in HIV-1 Infected and Uninfected SubjectsPLOS ONE, 2013
- CD8 Encephalitis in HIV-Infected Patients Receiving cART: A Treatable EntityClinical Infectious Diseases, 2013
- Encephalitis with Infiltration by CD8+ Lymphocytes in HIV Patients Receiving Combination Antiretroviral TreatmentBrain Pathology, 2013
- The Addition of Mycophenolate Mofetil to Antiretroviral Therapy Including Abacavir Is Associated With Depletion of Intracellular Deoxyguanosine Triphosphate and a Decrease in Plasma HIV-1 RNAJAIDS Journal of Acquired Immune Deficiency Syndromes, 2002
- Dose proportional inhibition of HIV-1 replication by mycophenolic acid and synergistic inhibition in combination with abacavir, didanosine, and tenofovirAntiviral Research, 2002
- Case series assessing the safety of mycophenolate as part of multidrug rescue treatment regimensHIV Research & Clinical Practice, 2002
- A Pilot Study of the Use of Mycophenolate Mofetil as a Component of Therapy for Multidrug-Resistant HIV-1 InfectionJAIDS Journal of Acquired Immune Deficiency Syndromes, 2001
- MYCOPHENOLIC ACID INCREASES APOPTOSIS, LYSOSOMES AND LIPID DROPLETS IN HUMAN LYMPHOID AND MONOCYTIC CELL LINESTransplantation, 1999